Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
49
UTHR Quote, Financials, Valuation and Earnings
Last price:
$363.55
Seasonality move
:
6.42%
Day range:
$357.99 - $363.90
52-week range:
$208.62 - $417.82
Dividend yield:
0%
P/E ratio:
15.79x
P/S ratio:
6.38x
P/B ratio:
2.63x
Volume:
925.6K
Avg. volume:
333.7K
1-year change:
59.45%
Market cap:
$16.1B
Revenue:
$2.3B
EPS (TTM):
$22.77
Analysts' Opinion
-
Consensus RatingUnited Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $335.33, United Therapeutics has an estimated upside of 9.5% from its current price of $359.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $221.00 representing 100% downside risk from its current price of $359.58.
Fair Value
-
According to the consensus of 13 analysts, United Therapeutics has 9.5% upside to fair value with a price target of $335.33 per share.
UTHR vs. S&P 500
-
Over the past 5 trading days, United Therapeutics has overperformed the S&P 500 by 1.4% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
United Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
United Therapeutics has grown year-over-year revenues for 16 quarters straight. In the most recent quarter United Therapeutics reported revenues of $748.9M.
Earnings Growth
-
United Therapeutics has grown year-over-year earnings for 6 quarters straight. In the most recent quarter United Therapeutics reported earnings per share of $6.39.
Enterprise value:
13.1B
EV / Invested capital:
2.02x
Price / LTM sales:
6.38x
EV / EBIT:
8.82x
EV / Revenue:
4.76x
PEG ratio (5yr expected):
0.62x
EV / Free cash flow:
14.62x
Price / Operating cash flow:
19.58x
Enterprise value / EBITDA:
8.44x
Gross Profit (TTM):
$2.5B
Return On Assets:
16.09%
Net Income Margin (TTM):
40.31%
Return On Equity:
19.26%
Return On Invested Capital:
17.45%
Operating Margin:
54.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.9B | $2.2B | $2.8B | $609.4M | $748.9M | |
| Gross Profit | $1.7B | $2B | $2.5B | $539.3M | $665.8M | |
| Operating Income | $973.9M | $1.1B | $1.3B | $327M | $408.2M | |
| EBITDA | $987.8M | $1.3B | $1.6B | $380.7M | $417.8M | |
| Diluted EPS | $14.70 | $18.15 | $22.77 | $5.38 | $6.39 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.9B | $2.4B | $3.1B | $3.5B | $4B | |
| Total Assets | $4.4B | $5B | $5.8B | $7B | $7.1B | |
| Current Liabilities | $258.9M | $320M | $315.9M | $744.1M | $873.4M | |
| Total Liabilities | $1.1B | $1.2B | $1.2B | $1.3B | $1B | |
| Total Equity | $3.3B | $3.8B | $4.6B | $5.7B | $6.1B | |
| Total Debt | $800M | $800M | $800M | $800M | $400M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $848.9M | $955.5M | $1.1B | $346.2M | $377.2M | |
| Cash From Investing | -$818M | -$951M | $582.5M | -$313.4M | -$114.9M | |
| Cash From Financing | $27.4M | $136.4M | -$1.3B | $7.6M | -$64.1M | |
| Free Cash Flow | $679M | $764.3M | $898.1M | $280.5M | $300.7M | |
UTHR
Sector
Market Cap
$16.1B
$43.9M
Price % of 52-Week High
86.06%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
6.83%
-0.74%
1-Year Price Total Return
59.45%
-29.11%
Beta (5-Year)
0.544
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$364.41
200-day SMA
Buy
Level
$315.65
Bollinger Bands (100)
Buy
Level
338.58 - 376.24
Chaikin Money Flow
Buy
Level
92.4M
20-day SMA
Sell
Level
$368.45
Relative Strength Index (RSI14)
Sell
Level
43.55
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-72.284
50-day SMA
Sell
Level
$370.25
MACD (12, 26)
Sell
Level
-2.54
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
101.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.8257)
Buy
CA Score
(Annual)
Level (2.034)
Sell
Beneish M-Score
(Annual)
Level (-2.0594)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-5.2242)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Stock Forecast FAQ
In the current month, UTHR has received 7 Buy ratings 6 Hold ratings, and 0 Sell ratings. The UTHR average analyst price target in the past 3 months is $335.33.
-
Where Will United Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that United Therapeutics share price will rise to $335.33 per share over the next 12 months.
-
What Do Analysts Say About United Therapeutics?
Analysts are divided on their view about United Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that United Therapeutics is a Sell and believe this share price will drop from its current level to $221.00.
-
What Is United Therapeutics's Price Target?
The price target for United Therapeutics over the next 1-year time period is forecast to be $335.33 according to 13 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is UTHR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for United Therapeutics is a Buy. 7 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of UTHR?
You can purchase shares of United Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase United Therapeutics shares.
-
What Is The United Therapeutics Share Price Today?
United Therapeutics was last trading at $363.55 per share. This represents the most recent stock quote for United Therapeutics. Yesterday, United Therapeutics closed at $359.58 per share.
-
How To Buy United Therapeutics Stock Online?
In order to purchase United Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
